Advanced Solid Malignancies Clinical Trial
Official title:
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in 490 participants with advanced cancer that has recurred/progressed.
This is a modular phase I/IIa, multi-centre, multi-part, open-label, dose escalation, and dose expansion study. Approximately 490 participants will be enrolled and assigned to study treatments. This study consists of individual modules each evaluating safety and tolerability. - Core protocol which contains information applicable to all modules. - Module 1 (AZD9574 monotherapy): This module will include 220 participants: - Part A (dose-escalation cohorts) will include 130 participants (including backfills) with advanced/relapsed ovarian, breast, pancreatic or prostate cancer that are deemed suitable for a Poly ADP-Ribose Polymerase (PARPi) by the Investigator. - Part B (dose-expansion cohorts): This module will include up to 3 expansion cohorts with 30 participants in each: - Cohort B1 will include participants with advanced/relapsed Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer participants with BRCA mutated (BRCA1m, and BRCA2m), PALB2 mutation (PALB2m), RAD51Cm or RAD51Dm, without evidence of brain metastasis at baseline Magnetic Resonance Imaging (MRI) scan. - Cohort B2 will include participants with advanced/relapsed HER2-negative breast cancer participants with BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, who have either untreated or treated brain metastases that are not requiring immediate local therapy. - Up to of 20 participants may be required to get 12 evaluable participants in each cohort for food effect and Acid Reducing Agent (ARA) investigations. • Module 2 (AZD9574 in combination with temozolomide (TMZ): - Part A (dose-escalation cohorts) will include 75 participants with Isocitrate Dehydrogenase (IDH)-mutant glioma. • Module 3 (PET Sub-study: AZD9574 monotherapy [Panels 1 and 3), AZD9574 in combination with TMZ (Panel 2). This module will include 12 participants and is only applicable for Sweden. - Panel 1 (AZD9574 monotherapy) will include up to 8 participants with advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm. - Panel 2 (AZD9574 + TMZ) will include up to 2 participants with IDH-mutant recurrent glioma. - Panel 3 (AZD9574 monotherapy) will include up to 2 participants with breast cancer (without BM). - Module 4 (AZD9574 in combination with Trastuzumab deruxtecan [T-DXd]) This module will include 90 participants (including backfills): - Part A (dose escalation cohorts) will include participants with advanced, unresectable, or metastatic solid tumours that are HER2-positive. - Part B (dose expansion cohorts) may be added in the future following a protocol amendment. - Module 5 (AZD9574 in combination with Datopotamab deruxtecan [Dato-DXd]) This module will include 90 participants (including backfills): - Part A (dose escalation cohorts) will include participants with advanced, unresectable, or metastatic solid tumours in different types of cancers. - Part B (dose expansion cohorts) may be added in the future amendment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02080078 -
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
|
Phase 1 | |
| Completed |
NCT00981721 -
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Terminated |
NCT00351325 -
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT00295243 -
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT02347228 -
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Terminated |
NCT00979134 -
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
|
Phase 1 | |
| Completed |
NCT00997945 -
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT05573724 -
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT03736473 -
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
|
Phase 1 | |
| Completed |
NCT02260661 -
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Terminated |
NCT01219543 -
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
|
Phase 1 | |
| Completed |
NCT01213160 -
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
|
Phase 1 | |
| Completed |
NCT00572364 -
Open Label, Dose Escalation Phase I Study of AZD2281
|
Phase 1 | |
| Completed |
NCT03363893 -
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04606381 -
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05315167 -
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00879905 -
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00473616 -
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
|
Phase 1 | |
| Recruiting |
NCT05159700 -
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01813474 -
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
|
Phase 1 |